In vitro SMC treatment led to increased expression of GFAP and C3c in astrocytes, which can in turn lead to expression of other factors that enhance GBM growth, such as TGF-β, IL-6, and IGF-1 [69, 70]. The gene discussed is IL6; the disease is glioblastoma.